摘要
儿童急性淋巴细胞白血病（ALL）的疗效肯定,但成年人ALL疗效不甚理想.青少年处于儿童至成年人的过渡阶段,他们或接受儿童组化疗方案,或进入成年人医疗机构进行治疗.近年,国外大型协作组研究显示,青少年接受儿童方案的疗效好于成年人组.该文总结了国内外儿童和成年人化疗方案的差异,方案中非骨髓抑制性药物,特别是门冬酰胺酶的大剂量使用,可能是儿童方案在青少年ALL中取得较好疗效的主要原因.
The development of effective therapy for children with acute lymphoblastic leukemia （ALL） is one of the greatest successes of clinical oncology. However, cure rates for adults with ALL remain relatively low. Adolescents are the special population between children and adults. These patients group will be received protocol from either pediatric or adult oncologists depending on referral pattern. In recent years, researchers from abroad large cooperative groups show pediatric-based protocol has better outcome than adult-based protocol. In this article, the protocol of ALL in children and adults are compared . It seems the first and probably the most important reason is the dose intensity of the nonmyelosuppressive chemotherapeutic agents, especially asparaginase.
出处
《国际儿科学杂志》
2011年第1期38-40,共3页
International Journal of Pediatrics
